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Abstract
Background: The advent of biologic agents for the treatment of inflammatory bowel disease (IBD) was accompanied
in parallel with emerging understanding of persisting underlying inflammation and ensuing bowel damage that can
occur even in patients with seeming clinical remission. This lead to the concepts of mucosal healing and deep
remission gaining acceptance as the more desired goals for therapy within an ambitious disease-control
therapeutic approach, namely, treat-to-target strategy. However, how to practically monitor IBD patients, which
objective measures to follow, at what time-points and whether to act upon results in asymptomatic patients are all
questions that remain disputed.
Methods and result: In this concise review we aim to provide an overview of objective measures for monitoring of
IBD patients, focusing on the challenging group of patients treated by infliximab, adalimumab, vedolizumab and other
biologics. These objective measures are discussed in the context of the different common clinical scenarios wherein
the clinician may contemplate their use. Specifically, we will delineate the role of objective parameters to be monitored
during induction phase of treatment, during maintenance therapy, at loss of response and after elective cessation of
therapy in patients in remission.
Conclusion: Coupled with the non-negligible costs of therapy, and the over-all worse prognosis of moderate-severe
patients who are the usual recipients of biologic therapies, this challenging patients seem to be the first candidates for
this more proactive strategy combining inflammatory and pharmacokinetic monitoring of objective inflammatory and
pharmacokinetic measures. More data is still desirable to better define the exact parameters to be followed and their
optimal thresholds, and to delineate the optimal cost-effective interventions for these patients.
Background
The advent of novel biologics for the therapy of inflamma-
tory bowel disease (IBD) has substantially increased the
ability to induce and maintain remission of patients. With
clinical response and remission increasingly being achieved,
attention has spun to more ambitious goals, specifically
aiming at altering the natural debilitating course of these
diseases. This lead to investigations of objective markers, to
be set as surrogate goals for therapy thereby increasing the
probability of long-term favourable outcome. Taken to-
gether with the considerable costs of biologics, interest in
monitoring the therapy has risen not only for the purpose
of identifying markers that will serve as end-points for suc-
cessful treatment, but also for timely cessation or switching
of therapy in those unlikely to respond. In this concise
review we will examine emerging markers and strategies,
on which rational optimization of therapy of IBD may be
achieved with a focus on the optimization of biologic ther-
apies in different stages of treatment.
Before and during the induction phase of treatment
The single most important factor for optimization of ther-
apy for IBD at the initiation of treatment is ascertainment
of active IBD inflammation. While this may seem trivial,
one often finds various circumstances in clinical practice
lead to commencement of therapy without clear-cut indi-
cators of active inflammation and without rigorous
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exclusion of other aetiologies for symptoms. These man-
agement ‘short-cuts’ will ultimately lead to greater number
of patients being treated with immune-modulators and/or
biologics for symptoms arising from causes other than
active inflammation, subsequently increasing therapeutic
failure rate. For instance, in a real life cohort of 438
Crohn’s disease (CD) patients, elevated CRP was associ-
ated with three-time higher likelihood to respond to adali-
mumab induction [1]. Similar results were obtained with
infliximab from both real-life cohorts [2] and from sub-
analysis of ACCENT I infliximab Trial, whereby elevated
CRP at baseline was associated with better response to
induction and durable response [3]. However, it is notable
that depending on the outcome assessed, elevated baseline
CRP may also be associated with worse clinical outcome.
Thus, when a rigorous and severe outcome in the form of
future colectomy was assessed among infliximab treated
UC patients, high baseline CRP rather than a normal one
predicted higher infliximab failure as gauged by subse-
quent need for colectomy [4]. This probably reflects the
fact that the high-CRP population is enriched with genu-
ine inflammatory patients rather than diluted by some
IBD-IBS or by mild UC patients with favourable prognosis
regardless of therapy. It follows that evidence of baseline
inflammation should be correctly appreciated as a double-
edge sword. Thus, several studies showed higher medical
therapy failure rates in patients with very high level of
CRP or with severe endoscopic lesions, either among
patients with acute severe colitis [5] or with CD [6] receiv-
ing induction infliximab treatment. One interpretation of
these data may be to despair from medical therapy and
opt for early referral for surgical therapy, which may be
justified approach in some patients. However, an alterna-
tive interpretation may be that these patients with high in-
flammatory indices are afflicted with severe inflammatory
burden which will require more intensive medical therapy.
Indirect evidence that this may be the case was provided
by sub-analysis CHARM trial pertaining to the response
to weekly versus bi-weekly adalimumab therapy for high
versus low CRP groups [7]. Similarly, a retrospective ana-
lysis indicated an accelerated induction with Infliximab
may be superior to conventional induction in patients
with acute severe colitis when compared to a historic co-
hort [8], although no direct correlation with underlying
inflammatory burden grades was performed. Nonetheless,
whether pharmacokinetics in the form of inadequate
drug-exposure is the cause for most induction failures has
been challenged by a recent elegant study from Germany.
The investigators showed by fluorescent-conjugated adali-
mumab staining of mucosa during confocal endoscopic
microscopy that most patients who did not respond to
adalimumab had low burden of TNF+ mucosal cells [9].
These findings imply that most primary failures of anti-
TNF are due to inflammation propagated by non-TNF
mediated pathways, rather than by overwhelming TNF
burden that may justify an increase in the induction
dose. Indeed, there is conflicting pharmacokinetic data
regarding the usefulness of lower infliximab levels at
week 2 as predictors of subsequently failing versus
responding patients [10, 11].
Interestingly, while vedolizumab treated UC patients
with high-end quartile drug concentrations seemed to
enjoy higher rate of clinical response and remission at
week 6 [12], this is a somewhat a bewildering observa-
tion given the fact that even lower doses than tested in
the trial achieve near 100 % binding-saturation of the
alpha4beta7 target integrin [13]. Moreover, no clear cor-
relation was demonstrated between base-line inflamma-
tion in the form of calprotectin values above 500mcg/gr,
and the rate of response to therapy at week 6 [12]. Simi-
lar absence of clear-cut correlation between base line in-
flammatory indices and response/remission rates at
week 6 or week 54 were observed in the CD vedolizu-
mab trial [14]. Strikingly, in a recent real-life cohort of
172 UC and CD patients treated by vedolizumab, an ele-
vated CRP above normal value was the only predictor of
lack of response to induction with vedolizumab [15].
Thus, more data is needed to support or refute the
'baseline CRP paradigm' derived from anti-TNF experi-
ence in the realm of the anti-integrin agents.
Thickened bowel wall and increased blood perfusion are
typical features of inflammation and can be assessed by
bowel ultrasound, which could be used as a simple and
non-invasive technique for monitoring and optimizing the
biological treatment. In a study of 24 consecutive patients
receiving biological therapy, sonographic changes including
reduction in the thickness of the bowel wall and Doppler
blood flow were significantly more marked in Crohn’s pa-
tients who achieved clinical-biological response, compared
to those patients who did not respond to treatment [16]. In
another prospective longitudinal study of 30 patients
receiving immunomodulators and/or biological treat-
ment, 18 (60 %) patients exhibited endoscopic remis-
sion (CDEIS <6 points); of these patients, 15 (83.3 %)
had normalized sonographic findings, with a good cor-
relation between endoscopic remission and sonographic
normalization (κ = 0.73, p < 0.001) [17]. Transmural heal-
ing evaluated by bowel ultrasound can be achieved in 17
of 66 patients with CD treated with anti-TNF-[alpha]
agents and significantly correlates with MH.[18].
Fecal calprotectin (FC) has been shown to be useful in
predicting relapse of quiescent IBD patients [19]. In a
prospective study of UC patients on IFX, baseline FC
was not associated with risk of relapse,whereas two con-
secutive FC > 300 mg/kg had 100 % specificity for re-
lapse [20]. In another prospective study of UC patients
in clinical and endoscopic remission, FC > 100 had 65 %
of specificity and 88 % of NPV for relapse in 3 months,
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while FC > 250 had 85 % specificity, 88 % NPV for re-
lapse in 3 months [21].
Overall, the majority of data supports ascertaining ac-
tive inflammation and excluding other causes for symp-
toms as the most important objective measure to be
implemented before induction with biologic therapies.
Finer sub-groups distinction and even dichotomies may
exist regarding the influence of different values (i.e. very
high compared to high values) of inflammatory markers
elevation on the outcome of therapy, and merit further
studies. Additionally, sparse data indicates some value
for week 2 CRP normalization in UC patients as associ-
ated with long-term response [22], but whether there is
any role for routine monitoring of inflammatory and/or
pharmacokinetic indices during the induction phase it-
self remains to be determined.
After induction and during maintenance
It has been repeatedly shown that over half of the pa-
tient with CD in clinical remission may still have active
inflammation as gauged by biochemical and/or endo-
scopic measures [23, 24].
Monitoring of patients in the immediate time-point after
completion of induction seems to provide valuable clues
as to the persistence of residual inflammation, and can be
useful for identifying patients with high risk of unfavour-
able long-term outcome. For instance, normalization of in-
flammatory indices at week 10–14 of therapy, in the form
of calprotectin normalization and/or CRP normalization
or reduction, were found to predict long term outcomes
including clinical remission and mucosal healing by most
[25–29] but not all [30], studies. Along with reduction/
normalization of inflammatory indices, infliximab levels
higher than 3 to 4 mcg/ml at week 8 to 14 were also
shown to predict long term response to maintenance ther-
apy [25, 28, 31]. In a recent prospective observational
study of 93 patients in clinical remission after infliximab
induction, elevated CRP levels and infliximab drug levels
below 5.5 mcg/ml were predictive of subsequent loss of re-
sponse [32]. Thus, inflammatory and pharmacokinetic as-
sessment at the end of induction and at early stage of
maintenance phase may be justified in order to identify pa-
tients with high risk of therapy failure later on, in whom
pre-emptive measures may be indicated.
Moreover, in studies of repeated evaluations of inflam-
matory markers in patients in remission, elevation of
Calprotectin and CRP were shown to precede clinical
flares by 3–6 months, thereby allowing to identify pa-
tients with imminent risk of disease relapse, at least in
the short-medium time range [20]. Similarly, in the
ULTRA 3 extension study of adalimumab in UC pa-
tients, both increasing CRP levels and decreasing albu-
min concentrations during treatment were identified as
significant factors associated with a subsequent loss of
remission [33]. Calprotectin was not evaluated in this
study, but a metaanalysis of fecal calprotectin for pre-
dicting relapse in patients with quiescent IBD disclosed
comparable ability of calprotectin to predict relapse in
UC and CD patients, with an overall diagnostic area
under the curve of the receiver-operaor curve of 0.83
[19]. Coupled with inflammatory markers and pharma-
cokinetic measurements mentioned above, evolution of
immunogenicity, although also associated with reduced
drug levels, was shown to independently predict future
loss of response. In a prospective study of 125 IBD pa-
tients receiving infliximab, evolution of antibodies-to
infliximab (ATI) preceded clinical loss of response in
over 50 % of patients [34]. Similar results were reported
with a cohort of adalimumab-treated patients, in whom
20 % developed anti-adalimumab antibodies which pre-
dicted future biochemical and clinical loss of response
[35], and a two studies have found that anti-drug anti-
bodies even in the presence of circulating infliximab
levels, are associated with loss of response [36, 37].
Whether such inflammatory markers and/or pharmaco-
kinetic and immunogenicity abnormalities which antedate
clinical flares can be employed for actual change of man-
agement in patients in remission was hitherto investigated
by three clinical trials. In the landmark TAXIT trial, stable
patients under infliximab maintenance therapy (approxi-
mately 80 % were in complete clinical remission according
to clinical scores) were first dose-optimized to achieve
infliximab serum concentration between 3 to 7mcg/ml
and then randomly allocated to continued conventional
care or to therapeutic drug monitoring (TDM) -based
dose-optimization strategy [38]. Although the pre-defined
outcome of remission at week 52 was not different be-
tween the two arms, this was most likely due to study
design allowing dose-adjustments in both arms until trial
end-point. However, notably there was significant benefit
for TDM-based arm as gauged by less clinical flares dur-
ing the trial compared the standard treatment, indicating
the superiority of the proactive approach over the reactive
one in maintaining real enduring remission without
disease relapses. A second trial examined UC patients in
clinical remission yet with calprotectin levels above
50mcg/gr, and randomized them to continue same-dose
mesalamine treatment or to escalate the dose of the 5-
ASA [39]. This study found that escalating the dose of pa-
tients with clinical remission resulted in significant higher
rate of biochemical remission (Calprotectin <50mcg/gr) at
the end of the 6 weeks trial. Importantly, patients whose
calprotectin levels were above 200mcg/ml had shorter
relapse-free duration compared to those with calprotectin
levels below this threshold [39]. Finally, a Swedish trial
randomized UC patients in remission to an active arm of
5-ASA comprising of dose increase if calprotectin levels
rose above 300mcg/ml versus a continued treatment arm,
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in which patients continued same-dose 5-ASA regardless
of asymptomatic calprotectin elevations [40]. Only a nu-
meric trend in favour of the active arm, but not a statis-
tical significance difference, was found for the primary
outcome of number of relapses in the entire cohort during
the 18 month trial. However, the secondary outcome of
number of relapses among UC patients in remission with
calprotectin above 300mcg/ml has shown a significant re-
duction in clinical remission for the active arm, in which
pre-emptive dose-escalation was instituted [40]. Taken
together, the observational data about the correlation of
elevated inflammatory markers and/or evolving pharma-
cokinetic derangement with soon-to-follow clinical flares,
along with the above preliminary interventional data from
clinical trials, suggest that the possible usefulness of a pro-
active approach whereby therapy may need to be modified
in asymptomatic patients based on biochemical/pharma-
cokinetic monitoring. However, more controlled data is
needed to define the best cut-off to define the abnormal
values of the measured monitored parameters, the sub-
populations who will benefit the most and the type of
intervention which will be cost-effective.
At loss of response
Similar to the situation at the initiation of therapy, the
single most important factor to ascertain at the time of
loss of response is the presence of active IBD inflamma-
tion as the cause for re-emerging symptoms. Indeed,
myriad reasons may mimic a flare of IBD but will not be
amenable to optimization of the IBD-directed therapy
[41]. These include causes un-related to IBD, such as ir-
ritable bowel syndrome as well as aetiologies in-directly
related to IBD (super-imposed infections, cancer) and
even non-inflammatory causes directly related to the
IBD (fibrotic stricture, bile-salt diarrhoea). Thus, astute
management of patients with seeming loss of response
start with obtaining objective measures to verify active
inflammation is responsible for re-emerging symptoms,
either by biochemical indices or endoscopic/imaging evi-
dence. Once active IBD inflammation has been ascer-
tained, TDM data can be very useful in guiding the
therapeutic management. Thus, several observational
studies have shown that levels of drugs and anti-drug
antibodies correlate with response to common interven-
tions for loss of response [42–44]. Specifically, patients
with adequate drug levels and active inflammation will
usually respond better to switch to another class of
drugs. However, in selected cases, optimizing the anti-
TNF class may sometimes still be warranted for individ-
ual patients who may require higher concentrations for
response especially if they have exhausted other thera-
peutic modalities. Patients with low drug levels and low
titer anti-drug antibodies will generally respond to dose-
intensification, and patients with low drug levels and
high anti-drug antibodies will generally require to in-
class switch of biologic [41], or possibly to an addition
of an immunomodulator in attempt to revert immuno-
genicity [45].
Notably, however, these algorithms are still imperfect,
and were estimated to be able to guide therapy in 72 %
of patients, whereas PK/immunogenicity results may
come back in a grey-zone range for the remaining 28 %
of patients for whom future studies are needed to refine
TDM algorithms [44]. Nonetheless, it is important to
note that a small randomized clinical trial, showed sig-
nificant cost-savings of over 5000 euro for patients with
loss of response to infliximab managed by TDM-based
algorithm compared to standard dose-intensification
protocol, with comparable clinical outcomes [46]. Thus,
overall the role of TDM-guided therapy in patients with
loss of response seems quite established, and several al-
gorithms have been proposed to address this clinical sce-
nario [47, 48], although more data is still needed to
define the optimal thresholds for the different interven-
tions and to reconcile inter-assay differences.
Before and after stopping biologic therapy
A study of 52 patients from Finland, who stopped inflixi-
mab in deep remission after over one year of therapy, in-
cluded a mixed population of UC and CD patients and
could not identify factors predicting of relapse after ther-
apy cessation [49]. In contrast, in the STORI trial whereby
patients in clinical remission during combination therapy
with infliximab + immunomodulators stopped infliximab
therapy, elevation of calprotectin preceded and identified
future flaring patients. Moreover, patients who discontin-
ued infliximab while having clinical remission yet with ele-
vated CRP had higher risk of relapse, probably indicating
underlying asymptomatic inflammtion and lack of deep
remission in this subgroup [50]. Interestingly, patients
with low drug levels of infliximab, and even those with nil
levels of infliximab and adalimumab, before stopping anti-
TNF treatment during long-lasting remission, were found
by two separate studies to sustain lower risk of relapse
after anti-TNF cessation [50, 51]. This seemingly paradox-
ical finding indicates that a certain small subset of patients
possibly exist, in whom biologic therapy was useful for
induction of remission - deep enough to be maintained
later-on independent of a pharmacokinetic/immunogen-
icity problem that later arose. Thus, incidental low/un-
detectable drug levels in patients with long-term deep
remission may contra-intuitively identify patients whose
remission is no longer dependent on anti-TNF therapy for
its maintenance, and in whom the biologic may be discon-
tinued. At any rate, although more data is needed, there
seems to be a role for continued biochemical monitoring
of patients who have stopped biologic treatment in
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remission, with the aim of early identification of patients
at risk for relapse.
Role of endoscopy and mucosal healing assessment for
optimizing therapy
Throughout this review, we have focused on non-invasive
objective measures for monitoring IBD patients. However,
emerging data suggests that mucosal healing may be the
ultimate therapeutic goal which may be strongly associ-
ated with alteration of disease natural history and reduc-
tion of future complications and surgeries [52–55]. As
such, it is biologically reasonable that endoscopic assess-
ment of mucosal healing will provide superior prediction
power of future patient course compared to non-invasive
blood and stool parameters. A comprehensive assessment
of mucosal healing concept is beyond the scope of the
present review. However, it is notable that in a paediatric
prospective observational study of UC patients treated
with infliximab, MH at week 8 was better correlated with
one year corticosteroid remission compared to week 8
CRP level although not better than PUCAI clinical score
for this purpose [56] and MH was also found to be the
only factor predictive of future colectomy in a FENCH
cohort of UC patients treated with infliximab [54]. There-
fore, it is plausible to assume that mucosal healing, being
more closely correlated with absence of bowel wall ana-
tomic damage than surrogate biochemical indices of
inflammation, will better serve to identify patients at risk
for future relapses. In this respect, several studies recently
have pointed to levels of anti-TNF drugs that are associ-
ated with higher rates of mucosal healing, rather than
merely associate with clinical response [57, 58], and it is
likely that in the future, our target concentrations towards
which biologics dosing is adjusted will be governed by this
‘mucosal healing therapeutic drug window’.
In the randomised postoperative Crohn’s endoscopic
recurrence (POCER) trial, 177 consecutive patients
with Crohn’s disease undergoing intestinal resection of
all macroscopic disease received standard prophylactic
treatment with metronidazole and thiopurine, the later
given to patients with high-risk features. Patients were
then randomized into parallel groups: colonoscopy at
6 months (active care group, 122 patients) or no colonos-
copy (standard care group, 52 patients). In the case of
endoscopic recurrence (Rutgeerts score ≥ i2) at 6 months,
patients in active group stepped-up to thiopurine, fort-
nightly adalimumab with thiopurine, or weekly adalimu-
mab. The trial demonstrated that endoscopic recurrence
at 18 months occurred in 60 (49 %) patients in the active
care group and 35 (67 %) patients in the standard care
group (p = 0•03). Complete mucosal normality was main-
tained in 27 (22 %) patients in the active care group versus
four (8 %) in the standard care group (p = 0•03). This sug-
gests that treatment according to clinical risk of recurrence
coupled with early colonoscopy could play important role
in optimizing post-operative treatment [59]
However, even endoscopic mucosal healing may not
be the optimal marker, because careful studies have
shown histologic inflammation to persist in a subset of
patients with complete endoscopic healing of the mu-
cosa [60]. Moreover, histologic inflammation even in the
presence of complete mucosal healing was associated
with future relapse, [61]. Interestingly, while calprotectin
was found to correlate with mucosal healing in both CD
and UC patients [62], a recent small study has found
that in UC patients with clinical and endoscopic remis-
sion, low calprotectin was more useful to rule-out future
relapses compared to normal histology score [63]. This
illustrates the persisting challenges in defining the best
outcomes in endoscopy and biochemical analysis that
need to be jointly sought and combined for the purpose
of optimal risk-stratification of IBD patients. Moreover,
patient acceptability of repeated endoscopies is also a
common obstacle, and more patient-friendly techniques
for disease monitoring, especially for CD patients, may
be required. Whether these will include capsule endos-
copy and/or additional novel patient-friendly modalities
remains to be seen.
Conclusion
The plea for closer monitoring of IBD patients seems in-
creasingly justified as our understanding evolves to ac-
knowledge that patients’ clinical symptoms may reflect
the tip of the iceberg of underlying incessant inflamma-
tion and consequent future bowel damage. Coupled with
the non-negligible costs of therapy, and the over-all
worse prognosis of moderate-severe patients who are
the usual recipients of biologic therapies, this challen-
ging patients seem to be the first candidates for this
more proactive strategy combining inflammatory and
pharmacokinetic monitoring of objective inflammatory
and pharmacokinetic measures. More data is still desir-
able to better define the exact parameters to be followed
and their optimal thresholds, and to delineate the opti-
mal cost-effective interventions for these patients.
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